Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.

@article{Minoura2007MechanismBW,
  title={Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.},
  author={Hideaki Minoura and Shigeru Takeshita and Chiaki Kimura and Jiro Hirosumi and Shoji Takakura and Ikuo Kawamura and Jiro Seki and Toshitaka Manda and Seitaro Mutoh},
  journal={Diabetes, obesity & metabolism},
  year={2007},
  volume={9 3},
  pages={369-78}
}
AIM The aim of this study was to examine the mechanism by which a novel non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR) gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. METHODS FK614 (1, 3.2 or 10 mg/kg) and a TZD PPARgamma agonist, pioglitazone (1, 3.2 or 10 mg/kg), were orally administered to Zucker fatty rats (genetically obese and insulin resistant) once a day for 14 days, and an oral glucose tolerance test was performed. The… CONTINUE READING